 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
ABIOMED, Inc. (ABMD) provides medical devices in circulatory support and continuum of care in heart recovery to acute heart failure patients.
Its products consist of Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; Impella CP, a micro heart pump; and Impella 5.0 catheter and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite.
The company also manufactures and sells the Impella RP, a percutaneous catheter-based axial flow pump; and AB5000 circulatory support system and the BVS 5000 biventricular support system for temporary support of acute heart failure patients in profound shock, including patients suffering from cardiogenic shock after a heart attack, post-cardiotomy cardiogenic shock, or myocarditis.
In addition, it offers Symphony, a synchronized minimally invasive implantable cardiac assist device designed to treat chronic patients with moderate heart failure by improving patient hemodynamics; and AbioCor program.
The company sells its products through direct sales and clinical support personnel in the United States, Canada, Germany, France, the United Kingdom, and internationally.
Shares have formed a bullish "flag" after the the FDA approved its heart pump Impella 2.5. The FDA had first approved Impella in 2008, but in 2013 it reclassified the product as a class III device. The FDA's website says that class III items "are generally the highest risk devices and are therefore subject to the highest level of regulatory control." To gain broader market access, Abiomed had to run additional clinical trials to support the device's use in high-risk percutaneous coronary intervention (PCI) procedures, also known as angioplasty. Higher share prices are expected for this stock.
52-Weeks Trading Range: $20.29 - $74.70
Entry Point: $69.50
Stop Loss: $66.00
Taret Price: $76.45
ABMD fell below our stop loss. Closed at $65.00
